The primary market is set for a busy stretch next week, with Wakefit Innovations and Corona Remedies launching their initial public offerings on December 8, 2025, and NephroPlus’ on December 10, 2025. These companies have announced their price bands, issue structures, and fundraising plans. Grey-market buzz for Wakefit and Corona Remedies’ suggests healthy investor appetite ahead of subscription openings.
Key details of Corona Remedies IPO
Pharma company Corona Remedies, backed by private equity firm ChrysCapital, has fixed a price band of ₹1,008–1,062 per share, valuing the business at nearly ₹6,500 crore.
Its ₹655.37 crore issue is entirely an offer for sale (OFS) by promoters and existing investors, including Sepia Investments, Anchor Partners and Sage Investment Trust. Since the IPO does not offer fresh shares, the proceeds will go directly to the selling shareholders.
The subscription window runs from December 8, 2025, to December 10, 2025, with anchor investors participating on December 5, 2025. The revised issue size, trimmed from the originally planned ₹800 crore, reflects the company’s updated fundraising strategy.
JM Financial, IIFL Capital Services and Kotak Mahindra Capital Company are the book-running lead managers to the issue.
Corona Remedies is slated to list on the stock exchanges on December 15, 2025, and early grey-market indications point to potential listing gains, buoyed by strong sectoral sentiment in pharmaceuticals and the company’s stable revenue profile.
Key details of Wakefit Innovations IPO
Home and furnishings firm Wakefit Innovations is also launching its ₹1,289 crore IPO, comprising a fresh issue of ₹377.18 crore and an OFS of 4.67 crore shares valued at about ₹912 crore. The company has priced the issue at ₹185–195 per share, pegging its valuation close to ₹6,400 crore.
The issue opens on December 8, 2025, and closes on December 10, 2025, with anchor allocation scheduled for December 5, 2025.
Promoters Ankit Garg and Chaitanya Ramalingegowda, along with several institutional shareholders including Peak XV Partners, Verlinvest SA and Redwood Trust, will dilute their stakes through the OFS, bringing promoter holding down to roughly 37 per cent post-issue.
Axis Capital, IIFL Capital Services and Nomura Financial Advisory and Securities (India) Private Ltd are the book-running lead managers to the issue.
Wakefit plans to deploy a significant portion of the fresh capital towards expansion and other expenses.
Mixed brokerage sentiment for Corona Remedies and Wakefit
Brokerage views on both offerings suggest cautious optimism. Analysts note that Corona Remedies’ strong financial track record and diversified product basket position it well for long-term growth, though the absence of fresh capital limits immediate operational impact.
SBI Securities acknowledged the company’s healthy return ratios, lean balance sheet, and valuations, which are in line with peers, and recommended that investors subscribe to the issue at the cut-off price.
For Wakefit, brokerages highlight the brand’s rapid scale-up in India’s organised home and sleep solutions market, its omnichannel footprint and the long runway for growth. However, some caution that retail expansion and marketing-led brand building could weigh on margins in the near term. In both cases, strong grey market premium trends are fueling expectations of healthy listings, provided broader market conditions remain supportive.
SBI Securities has recommended that investors avoid the issue and track the company’s performance post-listing.
NephroPlus’ ₹871-crore IPO opens on December 10
Nephrocare Health Services Ltd, a dialysis services provider known for its brand NephroPlus, has announced a price band of ₹438–460 per share for its upcoming ₹871-crore IPO, valuing the company at over ₹4,600 crore. The public issue will open from December 10, 2025, to December 12, 2025, with anchor bidding scheduled for December 9, 2025. The IPO comprises a fresh issue of shares worth ₹353.4 crore and an OFS of 1.12 crore shares valued at ₹517.6 crore at the upper price band.
Promoters Investcorp Private Equity Fund II, Healthcare Parent, Investcorp Growth Opportunity Fund, Edoras Investment Holdings Pte. Ltd, with other shareholders such as Investcorp India Private Equity Opportunity, International Finance Corporation and 360 One Special Opportunities Funds will offload shares.
The company will utilise the funds to open new clinics and to meet general corporate expenses.
Shares will likely debut on bourses on December 17, 2025.
ICICI Securities, Ambit, IIFL Capital Services and Nomura Financial Advisory and Securities (India) Private Ltd are the book-running lead managers to the issue.